TABLE 1.

Frequency of immunophenotypic alterations in bone marrow cell compartments (other than plasma cells) of patients with symptomatic multiple myeloma (MM) and smoldering multiple myeloma (SMM) at diagnosis, and SMM cases after induction therapy with nine courses of lenalidomide plus dexamethasone (Len/Dex).

TABLE 1.